NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China fo

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirmat

ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patients First-in-human SAD study in healthy volunteers expected to initiate Q3 2026 Phase 1b study in patients with ADPKD planned for the first half of 2027 ADPKD affects an estimated 12 million people worldwide; approximately 50% develop end-stage kidney disease SAN DIEGO and SUZHOU, China, July 07, 2026 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biot

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regula

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative so

-- Arbitration tribunal declared that PM647 is within Prime Medicine’s “Field”, confirming Prime Medicine’s right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which D

FDA pauses CRL disclosure plansPrime Medicine claims win in gene-editing dispute with BeamSeres touts early SER-155 data in cancer side effectBoehringer's oral IPF therapy cleared in UKFDA pauses CRL disclosure plansAn FDA spokesperson confirmed to FirstWord that a programme to publish complete response letters (CRLs) shortly after their issuance has been temporarily halted. The initiative, championed by then-FDA Commissioner Marty Makary, was intended to increase transparency within the agency

Bausch + Lomb said Thursday its investigational asset BL1107 failed to clear a mid-stage study in glaucoma, prompting the company to shelve the candidate's development as a topical eye drop for vision improvement and instead pivot to a sustained-release implant for geographic atrophy (GA)."Success in drug development is based on a portfolio, not a single programme," said Yehia Hashad, chief medical officer of Bausch + Lomb. "Not every programme will succeed, but every study helps us make smarter

SILICON VALLEY, Calif., July 9, 2026 /PRNewswire/ -- TibaRay, a Silicon Valley medical technology company founded on Stanford University research, announced today that its first Galactica™ cancer treatment systems have entered manufacturing. The milestone marks a major step for TibaRay as it moves its next-generation radiotherapy technology closer to patients. Continue Reading TibaRay's Galactica system has been designed for integration into the leading upright radiotherapy platform, allowing pa